Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double- stranded RNA-binding Domain Structure  James C Geoghegan, Brian L Gilmore,

Slides:



Advertisements
Similar presentations
Volume 70, Issue 7, Pages (October 2006)
Advertisements

Molecular Therapy - Nucleic Acids
Repression of COUP-TFI Improves Bone Marrow-Derived Mesenchymal Stem Cell Differentiation into Insulin-Producing Cells  Tao Zhang, Xiao-Hang Li, Dian-Bao.
Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide  Mostafa FN Abushahba,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 131, Issue 1, Pages (July 2006)
Molecular Therapy - Nucleic Acids
Volume 60, Issue 2, Pages (August 2001)
Volume 70, Issue 7, Pages (October 2006)
Requirement of heat shock protein 90 in mesangial cell mitogenesis
Molecular Therapy - Nucleic Acids
Expression of Protease-Activated Receptor-2 in SZ95 Sebocytes and its Role in Sebaceous Lipogenesis, Inflammation, and Innate Immunity  Sang E. Lee, Ji-Min.
The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation  Rixun Fang, Nilda A. Santiago, Lynne C. Olds,
Volume 76, Issue 1, Pages (July 2009)
Volume 135, Issue 1, Pages (July 2008)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 18, Issue 5, Pages (May 2010)
Sp1 Is Required for Glucose-Induced Transcriptional Regulation of Mouse Vesicular Glutamate Transporter 2 Gene  Tao Li, Liqun Bai, Jing Li, Suzu Igarashi,
Volume 14, Issue 4, Pages (October 2006)
Molecular Therapy - Nucleic Acids
Volume 65, Issue 5, Pages (May 2004)
Volume 19, Issue 12, Pages (December 2011)
Molecular Therapy - Nucleic Acids
Volume 124, Issue 4, Pages (April 2003)
Targeting Insulin Receptor with a Novel Internalizing Aptamer
Molecular Therapy - Nucleic Acids
Haiyan Dong, Ji Ma, Jie Wang, Zai-Sheng Wu, Patrick J Sinko, Lee Jia 
Molecular Therapy - Nucleic Acids
Volume 22, Issue 2, Pages (February 2014)
SUMO Promotes HDAC-Mediated Transcriptional Repression
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
An Acetylation Switch in p53 Mediates Holo-TFIID Recruitment
Volume 29, Issue 2, Pages (February 2008)
Microtubule-Targeted Drugs Inhibit VEGF Receptor-2 Expression by both Transcriptional and Post-Transcriptional Mechanisms  Markus Meissner, Andreas Pinter,
Erythropoietin stimulates proliferation of human renal carcinoma cells
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Noritaka Oyama, Keiji Iwatsuki, Yoshimi Homma, Fumio Kaneko 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 23, Issue 12, Pages (December 2015)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Nerve Growth Factor Receptor-Mediated Gene Transfer
Repression of COUP-TFI Improves Bone Marrow-Derived Mesenchymal Stem Cell Differentiation into Insulin-Producing Cells  Tao Zhang, Xiao-Hang Li, Dian-Bao.
Volume 67, Issue 4, Pages (April 2005)
Molecular Therapy - Nucleic Acids
In Vivo Tracking of Mesechymal Stem Cells Using Fluorescent Nanoparticles in an Osteochondral Repair Model  Jong Min Lee, Byung-Soo Kim, Haeshin Lee,
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
In vivo SELEX for Identification of Brain-penetrating Aptamers
Volume 21, Issue 1, Pages (January 2013)
Lawrence M. Pfeffer, Andrzej T. Slominski 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action  Markus Meissner, Monika.
Molecular Therapy - Nucleic Acids
Triplex-forming Peptide Nucleic Acids Induce Heritable Elevations in Gamma-globin Expression in Hematopoietic Progenitor Cells  Joanna Y Chin, Faisal.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Oncolytics
Volume 14, Issue 2, Pages (April 2004)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
Sven Kruspe, Cindy Meyer, Ulrich Hahn 
Presentation transcript:

Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double- stranded RNA-binding Domain Structure  James C Geoghegan, Brian L Gilmore, Beverly L Davidson  Molecular Therapy - Nucleic Acids  Volume 1, (January 2012) DOI: 10.1038/mtna.2012.43 Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Structure of DRBD fusion proteins. N-terminal targeting domains are fused to either PKR RNA-binding motif 1 (DRBD1) or an RNA-binding domain containing both PKR motifs 1 and 2 (DRBD2). Short linker regions are indicated by solid, black lines. A 6x histidine tag (6xHis) at the C-terminus is used for purification. DRBD, double-stranded RNA-binding domain; PKR, protein kinase R. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Electrophoretic mobility gel shift assays of siRNA and dsDNA binding to DRBD fusion proteins or synthetic peptides. 1 μmol/l siRNA or dsDNA was incubated with varying concentrations of protein and their interaction measured by migration on a 6% acrylamide gel followed by staining with ethidium bromide. (a,b) Gel shift of siRNA binding to DRBD or PPS-DRBD with increasing molar ratios of protein to siRNA. (c) Gel shift of either siRNA or dsDNA binding to PTD-DRBD at different molar ratios. (d) Gel shift of 1 μmol/l siRNA interacting with synthetic peptides at either 20 or 40 μmol/l. DRBD, double-stranded RNA-binding domain; dsDNA, double-stranded DNA; PTD, protein transduction domain; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Electrophoretic mobility gel shift assays of siRNA and dsDNA binding to 2× DRBD fusion proteins. Nucleic acid binding was performed as in Figure 2. (a,b,d) Gel shift of 1 μmol/l siRNA or dsDNA incubated with 0, 1, 2, or 4 μmol/l protein before electrophoresis. (c) Gel shift of 1 μmol/l siRNA incubated with PPS-2× DRBD at concentrations up to 16 μmol/l. (e) Gel shift of siRNA incubated with PTD-2× DRBD and PTD-DRBD at a 20-, 40-, and 60-fold relative molar excess. DRBD, double-stranded RNA-binding domain; dsDNA, double-stranded DNA; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Gene silencing of HPRT mediated by different DRBD fusion proteins. HeLa cells were incubated with complexes at a final concentration of 50 nmol/l siRNA and 3 μmol/l protein for 24 hours and HPRT mRNA measured by reverse transcription and quantitative PCR (RT-qPCR). Expression is normalized to cells treated with NC1 siRNA, which is set equal to 1. Data are derived from three independent experiments and presented as mean ± SD. *P < 0.01 and **P < 0.0001, Student's t-test. DRBD, double-stranded RNA-binding domain; HPRT, hypoxanthine-guanine phosphoribosyltransferase; PTD, protein transduction domain; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Binding and internalization of siRNA/DRBD complexes. (a) Complexes containing fluorescent Cy3-labeled siRNA and PTD-DRBD, PTD-2× DRBD, PPS-2× DRBD, or Cy3 siRNA alone, were incubated with HeLa cells and then acid washed to remove extracellular complexes. Internalized siRNA was visualized by fluorescence microscopy. (b) Mean fluorescence intensity of internalized Cy3-labeled siRNA measured under the conditions used in a. Error bars are SD. (c) Internalized siRNA visualized 24 h after treatment with complexes in a. Bar of low magnification images in a is 200 μm and in the high magnification inset images is 25 μm. Bars in c are 25 μm. a.u., arbitrary units; DRBD, double-stranded RNA-binding domain; PTD, protein transduction domain; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Silencing of HPRT mediated by DRBD fusion proteins in the presence or absence of chloroquine. (a) HeLa cells were treated with complexes at a concentration of 50 nmol/l siRNA and 3 μmol/l protein in the presence of 50 μmol/l chloroquine. HPRT levels were measured by reverse transcription-quantitative PCR 24 hours after treatment. (b) HeLa cells were treated with complexes at a concentration of 50 nmol/l siRNA and 0.4 μmol/l protein in the presence or absence of chloroquine. Data are derived from three independent experiments and presented as mean ± SD. *P < 0.01, Student's t-test. DRBD, double-stranded RNA-binding domain; HPRT, hypoxanthine-guanine phosphoribosyltransferase; PTD, protein transduction domain; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Silencing of HPRT mediated by a DRBD fusion protein displaying the transferrin receptor-binding peptide B2. (a) HeLa cells were treated with complexes at a concentration of 50 nmol/l siRNA and 3 μmol/l protein in the presence or absence of 50 μmol/l chloroquine (Chl.), transferrin (Tf), and/or bovine serum albumin (BSA). Cells were preincubated with 5 μmol/l Tf or BSA 30 minutes before treatment with complexes. HPRT levels were measured by reverse transcription-quantitative PCR 24 hours after treatment. (b) Alignment of the B2 peptide sequence with the N-terminal polybasic domain of the mature prion protein (PrP). Data are derived from ≥3 independent experiments and presented as mean ± SD. DRBD, double-stranded RNA-binding domain; HPRT, hypoxanthine-guanine phosphoribosyltransferase; siRNA, small interfering RNA. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.43) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions